Sermorelin: Clinical Guide for Prescribing Practices
Sermorelin is a synthetic analog of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the naturally occurring 44 amino acid sequence. It is one of the most established and longest-used GH peptides in clinical practice, with a strong safety profile and extensive prescribing history.
Also Known As
How Sermorelin Works
Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of human growth hormone releasing hormone [3]. It binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase via Gs-protein coupling, which raises intracellular cAMP and triggers GH gene transcription and vesicular GH release [2]. Because it acts through the native GHRH receptor, pituitary negative feedback via somatostatin and IGF-1 remains intact, preventing supraphysiologic GH elevation.
Clinical Evidence
Sermorelin received FDA approval in 1997 as Geref Diagnostic for evaluating pituitary GH reserve, and was later approved as Geref for pediatric GH deficiency [3]. Clinical trials in adults demonstrated significant increases in lean body mass, reductions in body fat percentage, and improved sleep architecture over 12 to 24 weeks of daily use [1]. Long-term safety data from over a decade of clinical prescribing supports a favorable adverse event profile [4]. The brand product was discontinued for commercial reasons, not safety concerns [2].
Clinical Uses
Patient Selection and Screening
Appropriate candidates include adults with clinical signs of GH decline (increased visceral adiposity, decreased lean mass, poor recovery, impaired sleep quality) and confirmed low-normal or below-normal IGF-1 levels [1][4]. The long safety history makes sermorelin suitable for conservative prescribers and GH-naive patients [2]. Contraindications include active malignancy, untreated hypothyroidism (blunts response), and known pituitary structural disease. Requires intact pituitary function; patients with pituitary insufficiency will not respond adequately [3].
Dosing and Administration
Standard adult dosing is 200 to 300mcg subcutaneously once daily, administered 30 minutes before bedtime on an empty stomach [3]. Some protocols use 100mcg for initial titration over the first 1 to 2 weeks. Cycling options include 5 days on/2 days off or continuous daily dosing with periodic breaks (8 to 12 weeks on, 2 to 4 weeks off). Full clinical benefits typically manifest at 3 to 6 months [1][4]. Monitor IGF-1 at baseline, 6 weeks, and quarterly thereafter. Adjust dose to maintain IGF-1 within age-appropriate upper-normal range. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection, typically before bedtime. Dosing is usually 200-300mcg daily or 5 days per week.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Sermorelin is often the lowest-cost GH peptide option, with wholesale vial pricing typically ranging from $30 to $60 for a 4 to 6 week supply. Patient pricing commonly ranges from $200 to $400 per month. Its FDA-approval history and long safety record make it an easy entry point for practices new to peptide therapy, reducing perceived medicolegal risk [2][3]. It pairs well as a starter peptide before transitioning patients to combination protocols (CJC-1295/Ipamorelin) for enhanced results and higher program value.
FDA Category Status
Previously FDA-approved (Geref); currently available through compounding
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Sermorelin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
Why is sermorelin considered a 'safer' GH peptide?
Can sermorelin be combined with other GH peptides?
How long before patients see results with sermorelin?
References
- Vittone J et al. Effects of single nightly injections of GHRH (1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308
- FDA Drug Approval: Geref (sermorelin acetate) for injection
- Merriam GR et al. Growth hormone-releasing hormone treatment in normal aging. J Anti Aging Med. 2001;4(4):331-343
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Sermorelin Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Sermorelin Through Karpa